Skip to content
Checking whether you are signed in

Zoetis Inc.

ZTSNew York Stock ExchangeFull coverage

Price
Loading your watchlists

Latest dossier

AI-generated

General research and analysis by Moatsight, not personalized investment advice. We show, you decide. Disclaimers

How dossiers are written

Q3 of fiscal year 2026 · Published Nov 9, 2026, 11:49 PM UTC

Zoetis is the largest animal-health company by revenue, selling prescription medicines, vaccines and diagnostics for pets and farm animals, mostly through veterinarians. Its core pet franchises are losing price and share for the first time: in the third quarter of 2026 dermatology revenue fell 15.7% as cheaper rival drugs arrived, US companion-animal revenue fell 8%, and adjusted EPS rose only because the share count was 7.1% lower. Livestock and diagnostics are still growing, and management expects US approval of long-acting Cytopoint and Simparica Duo by the end of 2026, but says it will not plan for any improvement in competition in 2027. Moatsight estimates revenue of about $9.2 billion and free cash flow of about $2.25 billion over the next four quarters.

Read the dossier

What you pay

FigureAt the close5-yr median5-yr range
P/ENo value: no close yetNo value: no price history
EV/SalesNo value: no close yetNo value: no price history
EV/EBITDANo value: no close yetNo value: no price history
Price/FCFNo value: no close yetNo value: no price history
Market capNo value: no close yet
Net debt and other claims(enterprise value minus market cap)No value: no close yet
Enterprise valueNo value: no close yet

How the business is doing

FigureLast 12 months1-year change1-yearYearly, 3 years8 quarters
RevenueNo value: cannot be derivedNo value: cannot be derivedNo value: cannot be derivedEach quarter is listed in the row's details.
Diluted EPSNo value: cannot be derivedNo value: cannot be derivedNo value: cannot be derivedEach quarter is listed in the row's details.
Free cash flowNo value: cannot be derivedNo value: cannot be derivedNo value: cannot be derivedEach quarter is listed in the row's details.
Gross marginNo value: cannot be derivedNo value: cannot be derivedNo value: cannot be derivedEach quarter is listed in the row's details.
Operating marginNo value: cannot be derivedNo value: cannot be derivedNo value: cannot be derivedNo value: cannot be derived
Net marginNo value: cannot be derivedNo value: cannot be derivedNo value: cannot be derivedEach quarter is listed in the row's details.
Share count411.600M−7.1%(better for the company)−3.7%Each quarter is listed in the row's details.
How to read these figures
  • Last 12 months: the latest four reported quarters added up, or a figure computed from them. The share count is its latest quarter's average.
  • 1-year change: the last 12 months against the 12 months a year earlier. A margin's change is in percentage points (pp). On a Next 12 months row, it is Moatsight's estimate against the last 12 months.
  • Yearly, 3 years: the yearly rate over the last 3 years, compounded. For a margin, its average change a year in percentage points.
  • 8 quarters: the last 12 months at each of the latest 8 quarter ends, oldest on the left; the dot is the latest. The quarters themselves are on Financials.
  • n/m: not meaningful, such as a rate of change from a loss.
  • Color: a 1-year change in the gain color is better for the company, one in the loss color worse. The caret and the sign show which way it moved, and a row where lower is better says so in its details. Color judges the company's reported results, never its share price or Moatsight's estimates, and no other column is colored.

Price

No closing prices are stored for this listing yet.

Facts

Exchange
New York Stock Exchange · USD
Kind
Common stock
Security
Common Stock